Clinical-stage regenerative medicine company Regeneus Ltd (ASX: RGS) has been issued with a Notice of Intention from the European Patent Office for the grant of a new key patent for Regeneus’ lead stem cell technology platform Progenza.
CEO, Karolis Rosickas, said once granted, the patent gives Regeneus protection for Progenza for the treatment of pain in Europe through to 2032. This expands Progenza’s IP protection in Europe beyond the previously granted patent for the treatment of inflammatory conditions.
It is positive to see our patents being allowed and granted across the major European, US and Japanese markets,” Mr Rosickas said.
“This patent will help facilitate our discussions with commercial partners for licensing Progenza for the $85.5 billionglobal pain market.”
Sydney-based Regeneus is using stem cell technologies to develop a portfolio of novel cell-based therapies.
The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus.
